https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-22 / Zhonghua Yi Xue Za Zhi 2008 Jul;88(28):1956-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-22 / Zhonghua Yi Xue Za Zhi 2008 Jul;88(28):1956-602008-07-22 00:00:002019-02-15 09:23:40[Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-15 / Cancer Res. 2008 Jul;68(14):5955-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-15 / Cancer Res. 2008 Jul;68(14):5955-642008-07-15 00:00:002019-02-15 08:46:49Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-11 / Lung Cancer 2009 Feb;63(2):247-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-11 / Lung Cancer 2009 Feb;63(2):247-502008-07-11 00:00:002019-02-15 08:34:58Inoperable Pancoast tumors treated with hyperthermia-inclusive multimodality therapies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-11 / Cancer Immunol. Immunother. 2009 Mar;58(3):361-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-11 / Cancer Immunol. Immunother. 2009 Mar;58(3):361-712008-07-11 00:00:002008-07-11 00:00:00TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-10 / J. Viral Hepat. 2008 Nov;15(11):782-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-10 / J. Viral Hepat. 2008 Nov;15(11):782-92008-07-10 00:00:002019-02-15 08:37:35Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-09 / Vaccine 2008 Aug;26(36):4716-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-09 / Vaccine 2008 Aug;26(36):4716-242008-07-09 00:00:002023-03-07 13:11:25Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-512008-07-01 00:00:002019-02-15 09:19:24Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-412008-07-01 00:00:002019-02-15 09:19:25Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-622008-07-01 00:00:002019-02-15 09:19:26IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-82008-07-01 00:00:002019-02-15 09:19:26Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
